Clinical trials: Cancer Progression
Breast Cancer
A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
This international, multicenter, randomized, double-blinded, placebo-controlled study is designed to compare the efficacy and safety of taselisib + fulvestrant with that of placebo + fulvestrant in postmenopausal women with…
- Trial name
- SANDPIPER (NCT02340221)
- Testing
- Taselisib, Fulvestrant
- Where
- 157 sites in United States, Australia and 26 more
- Volunteers
- 631 people
- Sponsor
- Hoffmann-La Roche
Glioblastoma, Astrocytoma
Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
The purpose of this study is to evaluate the efficacy of temozolomide on a protracted schedule, after standard 5-day temozolomide regimen in patients with recurrent or progressive high grade glioma.
- Conditions
- Glioblastoma, Astrocytoma, Oligodendroglioma, Brain Tumor, Recurrent
- Trial name
- NCT00575887
- Testing
- Temozolomide
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people
- Sponsor
- Marmara University
Melanoma
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation.
- Trial name
- NCT03455764
- Testing
- MCS110, Dabrafenib, Trametinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Dana-Farber Cancer Institute
Arthritis, Psoriatic
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
- Trial name
- APEX (NCT04882098)
- Testing
- Guselkumab
- Where
- 280 sites in United States, Australia and 27 more
- Volunteers
- 1,054 people
- Sponsor
- Janssen Research & Development, LLC
Hypertension, Prehypertension
Use of Mobile Technology to Prevent Progression of Pre-hypertension in Latin American Urban Settings
Nearly half of the adult population in Latin American urban settings has abnormally high blood pressure. Although half of these subjects with high blood pressure are still in the pre-hypertensive stage (systolic blood pressure…
- Trial name
- NCT01295216
- Testing
- Mobile technology to promote lifestyle modification
- Where
- 3 sites in Argentina, Guatemala and 1 more
- Volunteers
- 637 people
- Sponsor
- Institute of Nutrition of Central America and Panama
Renal Function
Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients
This study is designed to evaluate if early conversion to everolimus from cyclosporine in de novo renal transplant recipients can improve long-term renal function and slow down the progression of chronic allograft nephropathy
- Trial name
- NCT00634920
- Testing
- everolimus, cyclosporine A, Enteric Coated Mycophenolate Sodium (EC-MPS)
- Where
- 8 sites in Denmark, Norway and 1 more
- Volunteers
- 204 people
- Sponsor
- Novartis Pharmaceuticals
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma
Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
This phase II/III trial compares the effect of the combination treatment with olaparib and temozolomide to trabectedin or pazopanib (two of the most common chemotherapy drugs used as usual approach) in patients with uterine…
- Conditions
- Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
- Trial name
- NCT05432791
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 145 sites in United States, Puerto Rico
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Coronary Artery Disease (CAD), Coronary Atherosclerosis
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
The study will assess the change in coronary atherosclerotic disease as determined by intravascular ultrasound (IVUS) for aliskiren compared to placebo when given in addition to standard therapy in patients with coronary artery…
- Trial name
- AQUARIUS (NCT00853827)
- Testing
- Aliskiren
- Where
- 129 sites in United States, Argentina and 9 more
- Volunteers
- 613 people
- Sponsor
- Novartis Pharmaceuticals
Sepsis, Disease Progression
Venous Lactate in Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients in Emergency Department
To investigate the role of initial venous lactate in predicting the severity progression to overt septic shock and 30-day mortality in non-elderly patients without hemodynamic shock who suspected to have acute infections.
- Conditions
- Sepsis, Disease Progression, Septic Shock, Fatal Outcome
- Trial name
- NCT01947127
- Where
- Thailand
- Volunteers
- 458 people
- Sponsor
- Chulalongkorn University
Respiratory Syncytial Virus Infection
A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection
The purpose of this study is to learn about the safety and effects of sisunatovir. Sisunatovir is studied for the possible treatment of Respiratory Syncytial Virus (RSV).
- Trial name
- NCT06079320
- Testing
- Sisunatovir
- Where
- 19 sites in United States, China and 2 more
- Volunteers
- 16 people
- Sponsor
- Pfizer
Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype
A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis
This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Hereditary Transthyretin Amyloidosis using data that already exist in patients' medical records.
- Trial name
- NCT05139680
- Testing
- tafamidis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
A Study Of ¹²⁹XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications
This study will test whether daily use of azithromycin will reduce the rate of exacerbations and improve lung ventilation and perfusion assessed by XE-MRI.
- Trial name
- NCT04353661
- Testing
- Azithromycin, HP xenon (¹²⁹XE)
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Genentech, Inc.
Prediabetes, Type 1 Diabetes
Diabetes Prevention - Immune Tolerance
A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd® on the progression to type 1 diabetes in children with multiple islet cell autoantibodies Eligible children are 4 years or…
- Trial name
- DIAPREV-IT (NCT01122446)
- Testing
- Diamyd
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Lund University
Urothelial Carcinoma
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
There is no accepted standard chemotherapy approved for use in the second line for patients with advanced urothelial carcinoma whose cancer has progressed on combination chemotherapy including either cisplatin or carboplatin.
- Trial name
- NCT01437488
- Testing
- Cabazitaxel, Neulasta, CT Scan
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Colorectal Cancer
Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
This is a single arm open label pilot phase II trial of Regorafenib PO plus 5-FU/LV infusion in 15 mCRC patients who progressed on prior Regorafenib monotherapy as well as 5-FU containing chemotherapy combinations.The study will…
- Trial name
- NCT03099486
- Testing
- Regorafenib, 5-FU, Leucovorin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Fox Chase Cancer Center
Parkinson's Disease
Aerobic Exercise in Parkinson's Disease
Parkinson's disease (PD) is an incurable brain illness that afflicts more than one million Americans, including many aging Veterans.
- Trial name
- LTAE-PD (NCT03808675)
- Testing
- Aerobic walking, Usual care with PD specific health education
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- VA Office of Research and Development
Diabetes Mellitus, Type 1
STOP-T1D Low-Dose (ATG)
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D.
- Trial name
- TN28 (NCT04291703)
- Testing
- Antithymocyte Globulin
- Where
- 22 sites in United States, Australia
- Volunteers
- 2 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Covid19, Progression
Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression
Brief Summary: Purpose of this study is to evaluate efficacy of hydroxychloroquine (HCQ) in reducing progression of Corona Virus Disease 2019 (COVID - 19) and achieving viral clearance.
- Trial name
- COVID-19 (NCT04491994)
- Testing
- HCQ
- Where
- Pakistan
- Volunteers
- 540 people
- Sponsor
- UNICEF
Carcinoma, Renal Cell
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally…
- Trial name
- CONTACT-03 (NCT04338269)
- Testing
- Atezolizumab, Cabozantinib
- Where
- 135 sites in United States, Argentina and 13 more
- Volunteers
- 522 people
- Sponsor
- Hoffmann-La Roche
Anemia, Iron Deficiency, Hyperphosphatemia
Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
A 9-month randomized, double-blind, placebo-controlled study to compare the effect of fixed dose ferric citrate versus placebo in patients with advanced chronic kidney disease (eGFR ≤20 ml/min/1.73m2) on the composite endpoint of…
- Conditions
- Anemia, Iron Deficiency, Hyperphosphatemia, Renal Insufficiency, Chronic, Renal Anemia
- Trial name
- FRONTIER (NCT05085275)
- Testing
- Ferric Citrate 1 GM Oral Tablet [AURYXIA]
- Where
- 23 sites in United States
- Volunteers
- 289 people
- Sponsor
- USRC Kidney Research